iCAD Announces Compelling New and Real-World Data Demonstrating the Value of ProFound AI to be Presented at RSNA 2021
World’s first FDA
cleared AI breast cancer detection software to be highlighted in three
scientific presentations at largest radiological meeting in the world
iCAD’s innovative
breast health solutions, including ProFound AI Risk and PowerLook Density
Assessment, to be showcased during the meeting
NASHUA, N.H. – November 29, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced new and real-world research demonstrating the value
of ProFound
AI® for Digital Breast Tomosynthesis (DBT) will be highlighted at the 107th
Scientific Assembly and Annual Meeting of the Radiological Society of North
America (RSNA), November 28 – December 2. The Company is also showcasing its portfolio
of world-class breast health solutions, including the latest versions of ProFound AI® Risk and PowerLook®
Density Assessment, at McCormick Place in Chicago in the South
Hall meeting suites 214-216.
“We are thrilled to have three important scientific presentations
at RSNA this year, as these abstracts provide compelling new and real-world
data regarding ProFound AI and the potential it offers to improve outcomes by
supporting the earlier detection of breast cancer,” said Stacey Stevens,
President of iCAD, Inc. “Our efforts to empower clinicians with deep-learning
technologies to optimize efficiency, confidence, and patient outcomes are
demonstrated by the unrivaled specificity of our breast imaging AI solutions
that are transforming breast cancer detection and risk-based personalized
screening.”
In a poster presentation titled “Use Of Artificial Intelligence
Software To Identify Clinically Aggressive Lesions On Prior Digital Breast
Tomosynthesis Exams Based On Molecular Subtypes,” lead author Mary F. Ice,
MD, radiologist at Rose Imaging Specialist and Solis Mammography, will discuss
her research evaluating the use of ProFound AI in identifying and scoring
lesions in prior DBT screening exams of cancer cases (session ID:
SPR-BR-4).
Additionally, the following poster discussions will take place on
Tuesday, November 30:
– 12:15 to 12:45 pm (session
ID: BR03-A2):
“Effect Of Artificial Intelligence
Software On Digital Breast Tomosynthesis Screening Cancer Detection And
Abnormal Interpretation Rates Among Subspecialized Breast Radiologists: A Real-World
Experience.” Principal investigator Haley P. Letter, MD, Assistant
Professor, Program Director of Breast Imaging and Intervention Fellowship and
Associate Clerkship Director at University of Florida Health – Jacksonville, will
present research from a real-world study assessing the impact of ProFound AI in
DBT screening exams.
– 12:45 to 1:15 pm (session
ID: BR03-B3):
“Tomosynthesis-driven AI-derived
Breast Cancer Scoring Among A Racially Diverse Cohort Of Women Undergoing
Screening: Potential For Triage And Precision Cancer Screening.”
Principal
investigator Emily F. Conant, MD, professor
and chief, Division of Breast Imaging at the Hospital of the University of
Pennsylvania Medical Center, will discuss findings from an observational
study evaluating ProFound AI and the impact of race on the software’s performance
and Case Scores.
“Our research presented at RSNA this year
adds to the growing body of evidence supporting the importance of AI in breast
screening and women’s health,” said Dr. Conant. “The findings from our study
suggest that AI can be a valuable tool to help clinicians further personalize
and tailor breast cancer screening regimens for women, which may help to detect
cancers earlier, when they may be more easily treated.”
“ProFound AI delivers a level of precision, speed and efficacy
that is unrivaled in the industry. With more than 2,000 licenses
sold worldwide, ProFound AI offers multi-vendor compatibility and seamlessly
integrates into the diagnostic process,” continued Stevens. “Moreover,
ProFound AI is now compatible with Hologic Clarity HD, further demonstrating
our commitment to integrate with all major mammography system vendors and
enterprise-wide viewing applications.”
The Company’s full suite of breast health solutions includes the
latest generation of ProFound
AI for DBT, the first AI cancer detection software for DBT to be cleared by
the FDA, as well as ProFound
AI® for 2D Mammography, the latest generation of ProFound AI Risk for 2D and
3D mammography, and PowerLook
Density Assessment.
ProFound AI for DBT is proven to curtail workflow
challenges substantially by reducing radiologists’ reading time by 52.7
percent, thereby
reducing by half the amount of time it takes radiologists to read 3D
mammography datasets. Additionally, the platform is clinically proven to
improve radiologists’ sensitivity by 8 percent and reduce unnecessary patient
recall rates by 7.2 percent.[i]
The latest
generation of ProFound AI Risk offers the ability to calculate a short-term
risk estimation for 3D mammography, with greater accuracy compared to both the
previous version of the risk software based on 2D mammography and traditionally
used risk models. Expanded features include the ability to calculate short-term (one-, two- or three-year) absolute
risk based on either 2D or 3D mammography images. Specifically designed to
factor in racial and ethnic backgrounds, ProFound AI Risk also factors in
clinically relevant global screening guidelines and more than 15 country
incidence and mortality reference tables, for alignment with that country’s
general population.
The latest version of PowerLook Density Assessment software on the new PowerLook 10
platform enables clinicians to automate breast density assessment
accurately and reliably,[ii]
removing the challenges of subjectivity. It
identifies the patient’s anatomy, segments the breast, then measures adipose
and fibroglandular tissue and its dispersion to determine the density category
in alignment with BI-RADS® 5th Edition lexicon. Its consistent scores bring confident
density assessment and standardized stratification in density-based breast
cancer screening and reporting.
During the RSNA meeting this year, iCAD will also host “Cocktails
and Conversations” events on
November 29 and November 30, featuring leading AI experts in breast imaging who
will share their experience with ProFound AI. The events will take place at
Fatpour Tap Works McCormick at 5:30 pm CT on both days. To register for a
meeting with iCAD at RSNA or RSVP for an event, please visit: https://www.icadmed.com/rsna2021.html.
Headquartered in Nashua, NH, iCAD® is
a global medical technology leader providing innovative cancer detection and
therapy solutions.
For more information, visit www.icadmed.com.
Forward-Looking Statements
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements about the expected benefits of ProFound AI® Risk
for digital breast tomosynthesis (DBT) and the updated version of PowerLook®
Density Assessment, the benefits of the Company’s products, and future
prospects for the Company’s technology platforms and products. Such
forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results, performance,
or achievements of the Company to be materially different from any future
results, performance, or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the Company’s
ability to achieve business and strategic objectives, the willingness of
patients to undergo mammography screening in light of risks of potential
exposure to Covid-19, whether mammography screening will be treated as an
essential procedure, whether ProFound AI will improve reading
efficiency, improve specificity and sensitivity, reduce false
positives and otherwise prove to be more beneficial for patients and
clinicians, the impact of supply and manufacturing constraints or
difficulties on our ability to fulfill our orders, uncertainty of future sales
levels, to defend itself in litigation matters, protection of patents and other
proprietary rights, product market acceptance, possible technological
obsolescence of products, increased competition, government regulation, changes
in Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at https://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
Investor Relations:
Brian Ritchie,
LifeSci Advisors
+1-212-915-2578
###
[i] Conant,
E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of
Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial
Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
[ii]
iCAD data on file